• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Aplltd Share Price

    Alembic Pharmaceuticals Share PriceAlembic Pharmaceuticals

    Mid Cap 8.1k Result
    ₹765.9
    -7.7 (-1%)
    As on 11 December, 2023 | 10:38 BSE: 533573 NSE: APLLTDISIN: INE901L01018

    Alembic Pharmaceuticals Performance

    Day Range

    • Low 763.45
    • High 777.75
    ₹ 765.9

    52 Week Range

    • Low 462.30
    • High 839.00
    ₹ 765.9
    • Open Price775.00
    • Previous Close773.60
    • Volume28997

    Start SIP in Alembic Pharmaceuticals

    Start SIP

    Alembic Pharmaceuticals Share Price

    • Over 1 Month 4.52%
    • Over 3 Month 0.19%
    • Over 6 Month 29.6%
    • Over 1 Year 27.7%

    Alembic Pharmaceuticals Key Statistics

    P/E Ratio 28.3
    PEG Ratio 0.3
    Market Cap Cr 15,055
    Price to Book Ratio 3.4
    EPS 17.6
    Dividend 1
    Relative Strength Index 62.56
    Money Flow Index 87.81
    MACD Signal -1.53
    Average True Range 25.59

    Alembic Pharmaceuticals Investment Rating

    • Master Rating:

    • Alembic Pharmaceuticals has an operating revenue of Rs. 5,996.55 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 7% is okay, ROE of 7% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 17% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 7% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 50 which is a POOR score indicating inconsistency in earnings, a RS Rating of 58 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Alembic Pharmaceuticals Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 1,4791,3321,3071,3101,3541,1601,304
    Operating Expenses Qtr Cr 1,2711,1671,1381,0861,1091,0341,013
    Operating Profit Qtr Cr 207166169224245127291
    Depreciation Qtr Cr 67667466674646
    Interest Qtr Cr 151414151296
    Tax Qtr Cr 00-47252100
    Net Profit Qtr Cr 1349813111914672251
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 5,1535,087
    Operating Expenses Annual Cr 4,4854,127
    Operating Profit Annual in Cr 664909
    Depreciation Cr 273285
    Interest Annual Cr 4917
    Tax Annual Cr -1114
    Net Profit Annual Cr 347544
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 730545
    Cash from Investing Activity Annual Cr -461-369
    Cash from Financing Annual Activity Cr -261-217
    Net Cash Flow Annual Cr 8-40
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 4,4145,290
    Fixed Assets Annual Cr 2,9794,075
    Total Non Current Assets Annual Cr 3,3504,330
    Total Current Assets Annual Cr 2,7802,744
    Total Assets Annual Cr 6,1307,074
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 225269
    ROE Annual % 810
    ROCE Annual % 912
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1319
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 1,5951,4861,4061,5091,4751,2621,416
    Operating Expenses Qtr Cr 1,3871,2871,1941,2601,2421,2471,256
    Operating Profit Qtr Cr 20819921224923315160
    Depreciation Qtr Cr 686674676867123
    Interest Qtr Cr 161414151297
    Tax Qtr Cr -29-363318-2-2
    Net Profit Qtr Cr 137121153122133-6635
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 5,6555,356
    Operating Expenses Annual Cr 4,9444,432
    Operating Profit Annual in Cr 708874
    Depreciation Cr 275287
    Interest Annual Cr 5018
    Tax Annual Cr 13104
    Net Profit Annual Cr 342521
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 724552
    Cash from Investing Activity Annual Cr -448-372
    Cash from Financing Annual Activity Cr -262-217
    Net Cash Flow Annual Cr 14-37
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 4,3705,238
    Fixed Assets Annual Cr 3,0004,102
    Total Non Current Assets Annual Cr 3,2734,261
    Total Current Assets Annual Cr 2,9102,861
    Total Assets Annual Cr 6,1837,122
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 222266
    ROE Annual % 810
    ROCE Annual % 1012
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1317
    Invest in Alembic Pharmaceuticals

    Alembic Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹765.9
    -7.7 (-1%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹748.93
    • 50 Day
    • ₹748.94
    • 100 Day
    • ₹731.49
    • 200 Day
    • ₹695.23
    • 20 Day
    • ₹743.20
    • 50 Day
    • ₹756.31
    • 100 Day
    • ₹756.88
    • 200 Day
    • ₹655.17

    Alembic Pharmaceuticals Resistance and Support

    PIVOT
    ₹778.2
    Resistance
    First Resistance 791.35
    Second Resistance 809.10
    Third Resistance 822.25
    RSI 62.56
    MFI 87.81
    MACD Single Line -1.53
    MACD 4.15
    Support
    First Resistance 760.45
    Second Resistance 747.30
    Third Resistance 729.55

    Alembic Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 193,291 5,686,621 29.42
    Week 169,120 6,829,066 40.38
    1 Month 367,552 7,509,091 20.43
    6 Month 275,607 9,916,338 35.98

    Alembic Pharmaceuticals Result Highlights

    Alembic Pharmaceuticals Synopsis

    NSE-Medical-Generic Drugs

    Alembic Pharmaceutic is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 5149.00 Cr. and Equity Capital is Rs. 39.31 Cr. for the Year ended 31/03/2023. Alembic Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 16/06/2010 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ2010PLC061123 and registration number is 061123.
    Market Cap 15,058
    Sales 5,428
    Shares in Float 5.90
    No of funds 176
    Yield 1.03
    Book Value 3.44
    U/D Vol ratio 2.1
    LTDebt / Equity
    Alpha 0.06
    Beta 0.82

    Alembic Pharmaceuticals

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 69.61%69.61%69.61%69.61%
    Mutual Funds 7.33%6.64%6.47%5.87%
    Insurance Companies 6.57%6.74%6.55%6.6%
    Foreign Portfolio Investors 4.51%4.34%4.55%4.99%
    Financial Institutions/ Banks 0.03%0.03%0.04%0.04%
    Individual Investors 8.24%8.98%9.08%9.21%
    Others 3.71%3.66%3.7%3.68%

    Alembic Pharmaceuticals Management

    Name Designation
    Mr. Chirayu Amin Chairman & CEO
    Mr. Pranav Amin Managing Director
    Mr. Shaunak Amin Managing Director
    Mr. R K Baheti Director - Finance & CFO
    Mr. K G Ramanathan Independent Director
    Mr. Pranav Parikh Independent Director
    Mr. Paresh Saraiya Independent Director
    Dr. Archana Hingorani Independent Director
    Mr. Ashok Barat Independent Director
    Mr. Jai Diwanji Independent Director

    Alembic Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Alembic Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2023-11-07 Quarterly Results
    2023-08-04 Quarterly Results
    2023-05-05 Audited Results & Final Dividend
    2023-02-01 Quarterly Results
    2022-11-11 Quarterly Results
    Date Purpose Remarks
    2023-07-28 FINAL Rs.8.00 per share(400%)Final Dividend
    2022-08-18 INTERIM Rs.10.00 per share(500%)Dividend (Changed Final Dividend as Interim Divided)

    Alembic Pharmaceuticals MF Shareholding

    Name Amount(cr)
    Axis Small Cap Fund Regular Growth 16,369
    DSP Midcap Fund Growth 14,464
    Kotak Small Cap Growth 12,163
    DSP Small Cap Fund Regular Plan Growth 11,837
    DSP ELSS Tax Saver Fund Regular Plan Growth 11,693

    Alembic Pharmaceuticals FAQs

    What is Share Price of Alembic Pharmaceuticals ?

    Alembic Pharmaceuticals share price is ₹765 As on 11 December, 2023 | 10:24

    What is the Market Cap of Alembic Pharmaceuticals ?

    The Market Cap of Alembic Pharmaceuticals is ₹15054.8 Cr As on 11 December, 2023 | 10:24

    What is the P/E ratio of Alembic Pharmaceuticals ?

    The P/E ratio of Alembic Pharmaceuticals is 28.3 As on 11 December, 2023 | 10:24

    What is the PB ratio of Alembic Pharmaceuticals ?

    The PB ratio of Alembic Pharmaceuticals is 3.4 As on 11 December, 2023 | 10:24

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.